Home
Off-the-shelf
Humanized mice (target-specific)
genO-hPD‑1/hVISTA
Humanized mice (target-specific)

Preclinical double-humanized genO‑hPD‑1/hVISTA mouse model

The genO‑hPD‑1/hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or VISTA in fully immunocompetent mice.

Contact Us

Applications of the genO‑hPD‑1/hVISTA mouse model

Useful applications for researchers working on different biomedical fields, such as  immuno-oncology, immuno-inflammation and autoimmunity:

  • Assess the efficacy of PD-1 and/or VISTA-targeting compounds
    • Perform tumor growth inhibition assays in the context of monotherapies or combotherapies
    • Identify new possible therapies
  • Gain insights into the mechanism of action (MOA) of diverse constructs and their potential therapeutic benefits

‍

Features

  • Physiological regulation and expression pattern of human PD-1 and human VISTA
  • Preservation of the target-ligand interactions
  • Fully functional mouse immune system
  • Lack of expression of the murine target genes

Clients

No items found.

Supply & delivery

  • Breeding facilities in US and Europe
  • Delivery door-to-door worldwide
  • Certified health status from professional breeders

Related resources and publications

Adult-type granulosa cell tumor (AGCT)

castration-resistant metastatic prostate cancer (mCRPC)

CCR8

Chemokine

SIRPα

sirp-alpha

CD137

pulmonary embolism (PE)

osteomyelitis

hyperalgesia

PET imaging

intrauterine growth deficiency

Myopia

ossification

cGAS

cGAS-STING pathway

TFRC

FX-deficiency

muscle-eye-brain disease (MEB)

Tumor microenvironment

primary immunodeficiency (PID)

Oncology

Pharmacology

Neuroscience

Metabolism

Inflammation

Immunology

Respiration

Cardiovascular

Ophthalmology

Nephrology

Musculoskeletal

Hematology

Epigenetics

Development

Endocrinology

Dermatology

Humanization

Rosa26

TET system

Hprt

CreERt2

FLEx

innate immunity

Transgenesis

infection

vision

immune response

dementia

central nervous system (CNS)

taste

transplantation

autoimmunity

thermoregulation

sugar homeostasis

stress

skelet

pulmonary research

nutrition

pain research

muscle research

locomotion

memory

hearing

fat homeostatsis

tissue research

epigentic modification

drugs

cancer research

cell research

behavior

aging

stem cell research

reproductive research

lymphatic system

learning

heart research

gut research

genetic research

exercise

bone research

embryonic development

dental research

blood research

von Willebrand disease (VWD)

X-linked adrenoleukodystrophy (X-ADL)

Vanishing White Matter (VWM) disease

type 2 diabetes (T2D)

ulcerative colitis (UC)

type 1 diabetes (T1D)

thrombosis

thrombocytopenia

systemic lupus erythematosus (SLE)

tauopathy

stenosis

steatohepatitis

spinocerebellar ataxia type 2 (SCA2)

small cell lung cancer

SHORT syndrome

sepsis

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
PosterS
(
0
)
Scientific Articles
(
0
)
CommentarIes
(
0
)
Case studies
(
0
)
(Anaveon) ANV600, a cis-signaling αPD-1/IL-2Rβ/γ agonist, expands both CD4 + and CD8 + tumor specific T cells by acting in the tumor microenvironment and draining lymph nodes

Anti-tumor efficacy with hPD-1

Nov 2024
(Anaveon) ANV700 is a novel proximity-activated IL-21 receptor agonist designed to selectively reinvigorate tumor-reactive PD-1 expressing T cells

Efficacy assessment with hPD-1

Nov 2024
(Bonum) A Novel Method for Generating Regulated Cytokine Therapeutics: Safety and Activity of a Conditionally Active cLAG3-IL2 Capable of Delivering IL-2 to LAG-3+ Cells While Remaining Inert on LAG-3- Cells

Safety and activity of a conditionally active cLAG3-IL2

Apr 2024
(Cidara) Discovery of a multispecific CD73/PD-1 targeting Drug Fc-Conjugate (DFC), which improves tumor reduction compared to PD-1 monotherapy in a humanized mouse model

Multispecific CD73/PD-1 targeting

Apr 2024
(Anaveon) ANV600 is a novel PD-1 targeted IL-2Rβ/γ agonist that is combinable with therapeutic PD-1 inhibitors

Novel PD-1 targeted IL-2Rβ/γ agonist

Nov 2023
(Reaction Biology) Humanized PD-1 knock-in mice as a model system for combination therapies with human specific PD-1 therapeutics

hPD-1 to evaluate novel cancer therapies

Apr 2023
(Anaveon) ANV600 is a potent, cis-signaling, IL-2Rβ/γ directed IL-2 which efficiently expands intratumoral stem-like CD8 T cells

PD-1 & strong tumor growth inhibition

Apr 2023
Anti-VISTA agents profiling: complementarity of BRGSF-HIS and hVISTA Knock-in as preclinical models for immunotherapies

BRGSF-HIS & hVISTA for immunotherapies

Nov 2022
(Sensei) SNS-101, a monoclonal antibody that is highly selective for VISTA in the tumor microenvironment, demonstrates favorable pharmacokinetic and cytokine release characteristics and potentiates anti-PD-1 responsiveness

VISTA in the tumor microenvironment

Apr 2022
(Kineta) A Fully Human anti-VISTA Antibody as a Promising Therapy Against Poorly Immunogenic Tumors

anti-hVISTA against poorly immunogenic tumors

Apr 2021
(Charles River) Novel in vivo preclinical humanized models for the evaluation of human specific immune checkpoint inhibitors.

hPD-1/hCTLA-4 mice to evaluate immune checkpoint inhibitors

Nov 2019
(Charles River) Validation of humanized PD-1 knock-in mice as an emerging model to evaluate human specific PD-1 therapeutics

hPD-1 mice as a model to evaluate human specific PD-1 therapeutics

Mar 2019
Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with 89Zr-labelled CI-8993

Eur J Nucl Med Mol Imaging

Jul 2024
Highlighted article
read the comment
VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response

Nat Commun

Apr 2024
Highlighted article
read the comment
A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors

Front Immunol

Oct 2023
Highlighted article
read the comment
Human PD-1 agonist treatment alleviates neutrophilic asthma by reprogramming T cells

J Allergy Clin Immunol

Jul 2022
Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment

J Immunother Cancer

Jul 2022
An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy

Nat Cancer

Mar 2022
Highlighted article
read the comment
Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1 + Activated T Cells

Cancer Discov

Dec 2020
VISTA is an acidic pH-selective ligand for PSGL-1

Nature

Mar 2020
Highlighted article
read the comment
VISTA is a checkpoint regulator for naïve T cell quiescence and peripheral tolerance

Science

Dec 2019
Highlighted article
read the comment
A radiolabeled VISTA antibody for imaging VISTA expression

hVISTA - antibodies & PET imaging

7 min read
-
Oct 2024
VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response

VISTA - safety and PK profiling

8 min read
-
Apr 2024
A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors

Humanized VISTA mouse & Pharmacokinetics

10 min read
-
Dec 2023
CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity

Humanized ICP mouse and cell lines

9 min read
-
Jun 2023
A new promising family of small molecules regulating the PD-L1/PD-1 signaling pathway

Humanized PD-1/PD-L1 mouse and cell line

10 min read
-
Jul 2022
An alternative approach to immunotherapy: A bispecific agonist

Humanized PD-1 & GITR mouse

4 min read
-
Mar 2022
Uncoupling efficacy from toxicity: a case study on MEDI5752

Bispecific antibodies

5 min read
-
Apr 2021
A VISTA on naive T cell fate

Humanized ICP mouse

3 min read
-
Feb 2020
A new Nature report by Bristol-Myers Squibb provides new insights into VISTA biology and design of combination therapies

Humanized ICP in immuno-oncology

3 min read
-
Oct 2019
No results
No results

Validation data

Discover related products to

genO-hPD‑1/hVISTA

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
CD47
SIRPα
ICP (single-target)
ICP (multi-target)
Immune checkpoint

genO-hCD47/hSIRPα

Double-humanized genO‑hCD47/hSIRPα immunocompetent mice enable the efficacy assessment of anti-CD47/SIRPα.

‍

Immune checkpoint
CTLA-4
ICP (single-target)

genO-hCTLA‑4

The genO‑hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 in fully immunocompetent mice.

Immune checkpoint
CTLA-4
Lag3
ICP (multi-target)

genO-hCTLA‑4/hLAG3

The genO‑hCTLA-4/hLAG3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 and/or LAG3 in fully immunocompetent mice.

Immune checkpoint
OX40
ICP (single-target)

genO-hOX40

The genO-hOX40 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint OX40 in fully immunocompetent mice.

Immune checkpoint
CTLA-4
PD-1
ICP (multi-target)

genO-hPD‑1/hCTLA‑4

The genO‑hPD-1/hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or CTLA-4 in fully immunocompetent mice.

Immune checkpoint
PD-1
GITR
ICP (multi-target)
GITRL

genO-hPD‑1/hGITR/hGITRL

The genO-hPD-1/hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1, GITR and/or GITRL in fully immunocompetent mice.

Immune checkpoint
PD-1
PD-L1
ICP (multi-target)

genO-hPD‑1/hPD‑L1

The genO‑hPD-1/hPD-L1 mouse model enables in vivo efficacy assessment and profiling of molecules targeting the human PD-1/PD-L1 axis in fully immunocompetent mice.

Immune checkpoint
PD-1
TIM3
ICP (multi-target)

genO-hPD‑1/hTIM3

The genO‑hPD‑1/hTIM3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or TIM3 in fully immunocompetent mice.

CD137
ICP (single-target)
Immune checkpoint

genO‑hCD137

genO‑hCD137 immunocompetent mice enable the efficacy assessment of anti-CD137.

‍

Immune checkpoint
CD28
ICP (single-target)
T-cell engager

genO‑hCD28

The genO‑hCD28 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD28 in fully immunocompetent mice.

Immune checkpoint
CD39
ICP (single-target)

genO‑hCD39

The genO‑hCD39 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD39 in fully immunocompetent mice.

Immune checkpoint
GITR
ICP (single-target)

genO‑hGITR

The genO‑hGITR mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint GITR in fully immunocompetent mice.

Immune checkpoint
GITR
GITRL
ICP (multi-target)

genO‑hGITR/hGITRL

The genO‑hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of agonist and antagonist antibodies targeting human immune checkpoint GITR and/or GITRL in fully immunocompetent mice.

PD-1
Immune checkpoint
ICP (single-target)

genO‑hPD‑1

The genO‑hPD‑1 mouse enables the in vivo efficacy assessment and profiling of compounds targeting the human immune checkpoint PD-1 in fully immunocompetent mice

Immune checkpoint
PD-1
Lag3
ICP (multi-target)

genO‑hPD‑1/hLAG3

The genO‑hPD‑1/hLAG3 mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1 and/or LAG3 in fully immunocompetent mice.

Immune checkpoint
VISTA
ICP (single-target)

genO‑hVISTA

The genO‑hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint VISTA in fully immunocompetent mice.

PD-L1
Immune checkpoint
MC38
PD-1

genO-MC38-hPD-L1-LZ

The genO-MC38-hPD-L1-LZ clonal cell line expresses high levels of  human PD-L1 and forms solid tumors in vivo. An optimized version of a  luciferase-ZsGreen (LZ) fusion protein is also stably expressed for in vivo imaging and ex vivo tracking.

Preclinical double-humanized genO‑hPD‑1/hVISTA mouse model

Get in touch about

Let us know how we can help